Celcuity
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Minnesota, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
16305-36th Avenue North Ste 100, Minneap...Phone Number
(763) 392-0767Website
www.celcuity.comRevenue
-Stock Symbol
CELCIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
2
About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis.Explore more
Celcuity Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celcuity your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Celcuity launches new products
Congratulate Masked Content for being promoted to Masked Content at Celcuity
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Celcuity has new funding data
Check out if Celcuity is spiking on competitors!
Click to see if Celcuity had a recent Job posting/layoffs
Check if Celcuity has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Celcuity recently announced quarterly report
Celcuity, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Celcuity as Masked Content
Find more new buyers
Compare Similar Companies to Celcuity
Compare insights from companies similar to Celcuity, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$462.1M
1994
TC
Tracy ClementeChief People Officer & Chief Human Resources Officer
Company Profile Activity
Activity Insights
Celcuity is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Celcuity is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Celcuity.
Celcuity financials insights
Gather financial insights about Celcuity, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Multiple Rounds
$31.1M
2020
Debt
$350K
2021
Stock Offering
$24M
2024
Debt
$62M
Celcuity Tech Stack
A closer look at the technologies used by Celcuity
Most Recent Scoops
Project
Celcuity has reported Phase I-B data showing 48 months median progression-free survival for gedatolisib in the endocrine-sensitive frontline breast cancer population, compared to approximately 25 months for current CDK4/6 inhibitor standard of care, exceeding the estimated clinically meaningful benefit threshold of approximately 30 months.
Project
Celcuity has announced that VIKTORIA-2, its frontline Phase III program for advanced breast cancer, is structured as two concurrent studies enrolling both endocrine-resistant patients (approximately 440 patients, with data expected around end of 2028) and endocrine-sensitive patients (approximately 740 patients, with data expected in the 2030 timeframe).
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Medical Research
Person-Based
Product Launch, Pharmaceuticals
Celcuity News & Media
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that the U.S. Food and Drug Administration (“FDA”) approved REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer without a PIK3CA mutatiCelcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Celcuity Inc. (CELC) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 8:00 AM EDTCompany ParticipantsBrian Sullivan - Co-Founder,...Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increasedCelcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of its convertible senior notes due 2032 (the “Convertible Notes”).
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Celcuity
Sign Up For FreeTo access detailed company insights
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can ident... Read More
